Company / SG&A Expense
SUTRO BIOPHARMA, INC. SG&A Expense History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$48.5M
FY2025
5-year range
$32.6M / $59.5M
FY2021-FY2025
Trend
-18.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $56M to $48M over the past 2 years.
Based on SEC 10-K filings.
$48M in FY2025 with a 5-year CAGR of +17.8%.
Improved from $56M to $48M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +9.6%
- 5-Year CAGR
- +17.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +17.8%, indicating consistent growth.
- In FY2025, sg&a expense decreased 18.6% year-over-year.
- Peak sg&a expense was recorded in FY2024.
- Lowest sg&a expense in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score -3.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $48.5M | -18.6% |
| FY2024 | $59.5M | +6.3% |
| FY2023 | $56.0M | +52.1% |
| FY2022 | $36.8M | +13.0% |
| FY2021 | $32.6M | +52.4% |
| FY2020 | $21.4M | +30.6% |
| FY2019 | $16.4M | +10.5% |
| FY2018 | $14.8M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026